Axel S Merseburger, Ganesh Bakshi, Dong-Yi Chen, Edmund Chiong, Michel Jabbour, Jae Young Joung, Allen Yu-Hung Lai, Nathan Lawrentschuk, Tuan-Anh Le, Chi Fai Ng, Choon Ta Ng, Teng Aik Ong, Jacob See-Tong Pang, Danny M Rabah, Narasimhan Ragavan, Kazuhiro Sase, Hiroyoshi Suzuki, Michelle Mui Hian Teo, Hiroji Uemura, Henry H Woo
PURPOSE: Androgen deprivation therapy (ADT) is the mainstay approach for prostate cancer (PCa) management. However, the most commonly used ADT modality, gonadotropin-releasing hormone (GnRH) agonists, has been associated with an increased risk of cardiovascular disease (CVD). METHODS: The PCa Cardiovascular (PCCV) Expert Network, consisting of multinational urologists, cardiologists and oncologists with expertise in managing PCa, convened to discuss challenges to routine cardiovascular risk assessment in PCa management, as well as how to mitigate such risks in the current treatment landscape...
March 14, 2024: World Journal of Urology